miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway

被引:50
|
作者
Wan, Jun [1 ]
Ling, Xiean [1 ]
Peng, Bin [1 ]
Ding, Guanggui [1 ]
机构
[1] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Thorac Surg, 1017 DongMen North Rd, Shenzhen 518020, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
miR-142-5p; CD4(+) T cells; NSCLC; PD-L1; PTEN; ANTITUMOR; GENE; DIFFERENTIATION; POLYMORPHISMS; CARCINOMA; MODEL;
D O I
10.3892/or.2018.6439
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The present study aimed to evaluate the function of microRNA (miR)-142-5p on cancer immunity to induce apoptosis in human non-small cell lung cancer (NSCLC) and its mechanism. miR-142-5p expression was upregulated, and CD4(+) T cell levels were reduced in patients with NSCLC. Overexpression of miR-142-5p expression inhibited the cancer effects of CD4(+) T cells on NSCLC cell lines, and downregulation of miR-142-5p increased the cancer effects of CD4(+) T cells on NSCLC cell lines, compared with the control group. In addition, we found that overexpression of miR-142-5p suppressed PTEN protein expression and induced PI3K, p-Akt and PD-L1 protein expression in an in vitro model of NSCLC. Downregulation of miR-142-5p induced PTEN and PD-L1 protein expression and suppressed PI3K and p-Akt and protein expression in an in vitro model of NSCLC. The suppression of PD-L1 reduced the cancer effects of CD4(+) T cells on NSCLC cell lines following miR-142-5p downregulation. The inhibition of PTEN also reduced the cancer effects of CD4(+) T cells on NSCLC cell lines following miR-142-5p downregulation. Therefore, our study demonstrated that miR-142-5p regulated CD4(+) T cells in human NSCLC through PD-L1 expression via the PTEN pathway.
引用
收藏
页码:272 / 282
页数:11
相关论文
共 50 条
  • [41] Peripheral CD4+ cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer
    Liliang Xia
    Hui Wang
    Mingjiao Sun
    Yi Yang
    Chengcheng Yao
    Sheng He
    Huangqi Duan
    Weimin Xia
    Ruiming Sun
    Yaxian Yao
    Zhiwei Chen
    Qiong Zhao
    Hong Li
    Shun Lu
    Ying Wang
    Science China(Life Sciences) , 2021, (10) : 1590 - 1601
  • [42] Regulation of PD-L1 expression in non-small cell lung cancer by interleukin-1β
    Hirayama, Aiko
    Tanaka, Kentaro
    Tsutsumi, Hirono
    Nakanishi, Takayuki
    Yamashita, Sho
    Mizusaki, Shun
    Ishii, Yumiko
    Ota, Keiichi
    Yoneshima, Yasuto
    Iwama, Eiji
    Okamoto, Isamu
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [43] Significance of the Expression of PD-L1/PD-1 by Tumoral and Immune Cells in Non-Small Cell Lung Cancer.
    Ortiz-Villalon, C.
    De Petris, L.
    Kis, L.
    Yoshikawa, A.
    Ngoc, H.
    Roden, A.
    Fukuoka, J.
    Montero, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S948 - S948
  • [44] Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening
    Zhang, Xu-chao
    Cao, Xu
    Sun, Chun
    Xie, Zhi
    Guo, Jian-jun
    Yang, Jin-ji
    Yang, Xue-ning
    Dai, Hang-jun
    Li, Su-chun
    Xu, Xin-ran
    Zuo, Yun-xia
    Chen, Meng
    Koeppen, Hartmut
    He, Jing
    Kiermaier, Astrid
    Shames, David
    Cheng, Gang
    Wu, Yi-long
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (03) : 471 - 481
  • [45] Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening
    Xu-chao Zhang
    Xu Cao
    Chun Sun
    Zhi Xie
    Jian-jun Guo
    Jin-ji Yang
    Xue-ning Yang
    Hang-jun Dai
    Su-chun Li
    Xin-ran Xu
    Yun-xia Zuo
    Meng Chen
    Hartmut Koeppen
    Jing He
    Astrid Kiermaier
    David Shames
    Gang Cheng
    Yi-long Wu
    Cancer Immunology, Immunotherapy, 2018, 67 : 471 - 481
  • [46] PREDICTORS OF PD-L1 TESTING IN NON-SMALL CELL LUNG CANCER
    DiBonaventura, M.
    Meyers, A.
    Higginbottom, K.
    Morimoto, Y.
    Ilacqua, J.
    VALUE IN HEALTH, 2016, 19 (07) : A763 - A763
  • [47] Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells
    Rugamba, Alexis
    Kang, Dong Young
    Sp, Nipin
    Jo, Eun Seong
    Lee, Jin-Moo
    Bae, Se Won
    Jang, Kyoung-Jin
    CELLS, 2021, 10 (07)
  • [48] Durvalumab for the treatment of PD-L1 non-small cell lung cancer
    Naito, Tomoyuki
    Shiraishi, Hideaki
    Fujiwara, Yutaka
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (02): : 95 - 105
  • [49] Current PD-L1 immunohistochemistry for non-small cell lung cancer
    Scheel, Andreas H.
    Schaefer, Stephan C.
    JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1217 - 1219
  • [50] PD-L1 heterogeneity in patients with non-small cell lung cancer
    Wei, Zhigang
    Fan, Linlin
    Yang, Xia
    Li, Jie
    Zhan, Xuemei
    Ye, Xin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (05) : E268 - E274